investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Breast and Prostate Cancer Risk SNPs Regulate FoxA1 and Nuclear Receptor Activity
Mathieu Lupien
2 Collaborator(s)
Funding source
National Cancer Institute (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Mathieu Lupien
Ontario Institute for Cancer Research
Toronto, Canada
University Health Network
Toronto, Canada
Collaborator from Dartmouth College
Dartmouth College
Hanover, United States
Related projects
Irwin H Gelman
PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin/AKAP12
Prostate
Pathology
Partha Roy
Profilin as a Target to Suppress Invasive Breast Cancer
Breast
William Figg
Development of Drugs that Target Prostate Cancer
Prostate
Pathology
Pilar Blancafort
Targeted Epigenetic Silencing of Oncogenic Transcription Factors (PQ18)
Breast
Jing Yang
Regulation of Tumor Invasion and Metastasis by Matrix Stiffness
Breast
Natalie Fox
A portrait of functional associations of DNA and RNA in prostate cancer
Prostate
Kuo-Hsiung Lee
Novel Antitumor Agents
Breast
Che-Wei Chang
Systematic identification of resistance mechanisms to HER2-targeted therapies in breast cancer.
Breast
Dihua Yu
Enhancing Chemo-Response in Triple-Negative Breast Cancer by Activiating T-Cell Response
Breast